Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print.

Abstract

Not available.